A Phase 1 study of an engineered Treg cell therapy, GNTI-122, in adults with recently diagnosed Type 1 Diabetes Post author: Post published: November 20, 2026 Post category: Continue ReadingA Phase 1 study of an engineered Treg cell therapy, GNTI-122, in adults with recently diagnosed Type 1 Diabetes
First-in-human trial for EPI-321, a novel epigenetic therapy for FSHD targeting D4Z4 epigenome Post author: Post published: November 20, 2026 Post category: Continue ReadingFirst-in-human trial for EPI-321, a novel epigenetic therapy for FSHD targeting D4Z4 epigenome
Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS) Post author: Post published: November 20, 2026 Post category: Continue ReadingPhase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)
A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis Post author: Post published: November 20, 2026 Post category: Continue ReadingA Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis
SRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma Post author: Post published: November 20, 2026 Post category: Continue ReadingSRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome Post author: Post published: November 20, 2026 Post category: Continue ReadingPhase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome
A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease Post author: Post published: November 20, 2026 Post category: Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease
Phase I/II Clinical Trial for CMT4J Post author: Post published: November 20, 2026 Post category: Continue ReadingPhase I/II Clinical Trial for CMT4J
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) Post author: Post published: November 20, 2026 Post category: Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy Post author: Post published: November 20, 2026 Post category: Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy